ExomeNext: The New Generation of Diagnostic Exome Sequencing

  • Learn about:

    Our Rapid option for NICU patients (2-5 week TAT)

    How we achieve 37% diagnostic rate

    NoVA, our Novel-gene Variant Analysis process

     

Kelly Hagman

Senior Manager of Clinical Genomics

            Kelly Farwell Gonzalez received a B.A. in Psychobiology from Scripps College (the Claremont Colleges) and a M.S. in Genetic Counseling from the University of Arizona. Prior to her graduate studies, she spent several years in a research lab studying DNA mutagenesis. She later worked for more than four years as a senior genetic counselor at the Molecular Diagnostic Laboratory at City of Hope, where she continued her involvement in research, most of which focused on Li-Fraumeni Syndrome (LFS). She has more than 15 peer-reviewed publications in molecular genetics and has been an invited lecturer at several scientific meetings. Driven by her interest in new molecular technologies, Ms. Farwell Gonzalez joined Ambry in 2009 to lead the genomic services group where she gained expertise in multiple sequencing platforms and DNA/RNA enrichment techniques. Ms. Farwell Gonzalez currently leads Ambry's emerging clinical genomics offerings, most notably, the Clinical Diagnostic Exome, which allows her to draw on her expertise in next-gen sequencing, DNA mutagenesis, and genetic counseling.

Technical Laboratory Director

        Dr. Tippin received a B.S. in biological sciences and a Ph.D. in Molecular Biology from the University of Southern California where she received an NIH-NIA fellowship to research defects in DNA replication and repair mechanisms leading to human disease. She completed her post-doctoral training as an NIH Fellow in Clinical Molecular Genetics at the University of California, Los Angeles (UCLA) / Cedars Sinai Medical Center and is certified by the American Board of Medical Genetics. Prior to joining Ambry, Dr. Tippin was on the faculty at Harbor-UCLA Medical Center in the Division of Medical Genetics where her research focused on the development of novel molecular therapeutics for rare-genetic disorders, including lysosomal storage diseases and inherited forms of colon cancer.

  • Thu, May 8, 2014
  • 5:15pm PDT
  • Duration: 58 minutes
  • C.E.U. --
  • P.A.C.E. --

Search Results

Start your search...